Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Whitley Weatherford (NPI 1073073532)

Field	Value
Entity Type	Individual
Organization	Whitley Weatherford
Address	288 Anderson Bridge Rd
City	Scranton
State	SC
ZIP	29591
Taxonomy	Family Nurse Practitioner
NPI Enumerated	March 21, 2019

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider’s Medicare revenue footprint is concentrated in high-cost injectable biologic therapies: three J‑codes (J2350, J2357, J0897) individually account for large shares and the precomputed top‑3 codes account for 47.9% of total Medicare revenue. The presence of multiple monoclonal antibody and specialty injection codes (e.g., ocrelizumab, omalizumab, denosumab, rituximab, infliximab) indicates the practice is oriented toward administration of parenteral specialty drugs rather than primarily office visits or procedures. This revenue mix suggests an infusion/administration service line or specialty practice model that treats chronic immune-mediated or bone-related conditions.

J2357 (omalizumab) and J0897 (denosumab) are notable high-volume codes for this provider relative to national peers: J2357 ranks in the 94th percentile and J0897 ranks in the 98th percentile, signaling the provider is a substantially above-typical national volume participant for those therapies. In contrast, J2350 (ocrelizumab) sits in the middle of the national distribution at the 39th percentile, so activity for that specific product is unremarkable. These mixed competitive standings imply the provider is a meaningful regional supplier for certain biologic drugs but not uniformly dominant across all specialty agents.

Additional Medicare codes reinforce an infusion/chemotherapy-capable operation: J9312 (rituximab) and J1745 (infliximab) each contribute material revenue shares (14.4% and 12.2% respectively) and rank at the 88th and 96th percentiles nationally, respectively. The presence of chemotherapy administration codes and multiple infusion add‑ons (96413, 96415, 96365, 96366) further supports that the site delivers extended IV infusion services, including sessions exceeding one hour. The inclusion of both oncology/infusion administration CPTs and a mix of specialty biologic J‑codes suggests the practice manages longitudinal infusion therapies and may have the staffing and infrastructure to support repeated dosing regimens.

Revenue concentration is high: the precomputed top‑3 Medicare codes represent 47.9% of Medicare revenue, indicating nearly half of all Medicare receipts derive from a very small set of specialty drug administrations. That degree of concentration exposes the provider’s Medicare performance to demand or reimbursement changes affecting just a few products, and it positions those particular J‑codes as primary business drivers.

Payer mix is effectively single‑payer in operational terms: lifetime Medicare revenue is listed as $2.7M while there is no Medicaid billing on file, so this provider operates without a Medicaid revenue stream in the dataset. This makes the provider effectively Medicare‑dependent in the available claims record, which is important when assessing market exposure and contracting priorities.

Tenure is moderate: the NPI was enumerated on 2019-03-21 (approximately 7 years ago), indicating several years of established billing history to support the consistent accumulation of specialty administration claims. That tenure aligns with the development of a repeat infusion/patient base required to generate the observed volumes across high-frequency biologic agents.

There are several statistical outliers among administered services: 96415 (infusion add‑on) and 96372 (therapeutic injection) are flagged at the 99th percentile as extreme outliers, meaning this provider bills these administration-related codes at volumes far above typical national practice. These extremes, alongside high percentiles for multiple J‑codes, underscore an unusually heavy emphasis on infusion administration relative to most peers.

While several product codes are high-volume in absolute revenue, national rank percentiles vary: some specialty drugs (J2357, J0897, J1745) are notably above typical national volume, whereas others (J2350, J0129, J1306) fall in more typical percentile ranges. This pattern suggests the provider is a major regional administrator for a subset of biologics but maintains routine-level participation for other specialty agents, reflecting targeted service-line strengths rather than uniformly large scale across all injectables.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

20 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2350	Injection, ocrelizumab, 1 mg	10,800	$40	$453.6K
J2357	Injection, omalizumab, 5 mg	15,200	$30	$440.7K
J0897	Injection, denosumab, 1 mg	22,560	$20	$406.1K
J9312	Injection, rituximab, 10 mg	6,300	$60	$390.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	12,760	$30	$331.7K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	7,730	$30	$262.6K
J1306	Injection, inclisiran, 1 mg	18,740	$10	$168.7K
J3111	Injection, romosozumab-aqqg, 1 mg	13,650	$10	$109.2K
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	3,010	$20	$45.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	540	$80	$40.7K

Showing 1–10 of 20

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Whitley Weatherford — 6 of 20 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

20 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2350	4	10	10,800	$40	$546.8K
J0129	30	40	9,640	$30	$424.2K
J9312	3	20	2,340	$60	$193.7K
J2357	3	30	4,360	$30	$183.8K
J3111	17	40	12,390	$10	$129.4K
J1745	1	50	3,250	$30	$107K
J1306	2	20	8,800	$10	$95.1K
J0897	9	250	2,400	$20	$91.2K
J1439	31	30	42,750	$1	$42.3K
Q5103	1	10	2,760	$10	$34.9K

Showing 1–10 of 20

Related Providers

Other providers that share a Tax Identification Number (TIN) with Whitley Weatherford, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
Kristi Hunter	GA	General Practice Physician	$6.4M	$0
Rachel Tedesco	NC	Nurse Practitioner	$5.7M	$0
Stephen Parks	SC	Family Medicine Physician	$3.9M	$0
Lindsay Gamble	SC	Family Nurse Practitioner	$3.7M	$0
Lisa Sauls	SC	Family Nurse Practitioner	$3.4M	$0
Rosalee Unwin	SC	Family Nurse Practitioner	$2.9M	$0
Glenda Collins	SC	Family Nurse Practitioner	$2.3M	$0
James Montgomery	SC	Gynecology Physician	$1.9M	$0
Eliza Shinall	GA	Family Nurse Practitioner	$1.5M	$0

Whitley Weatherford — Billing Profile & Reimbursement Data

Sign up for Whitley Weatherford — Billing Profile & Reimbursement Data policy alerts

Whitley Weatherford — Billing Profile & Reimbursement Data

Sign up for Whitley Weatherford — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Frequently Asked Questions

References